Database | Recombinant Antibodies And Mimetics Database

What can we help you find?

You are searching for:

Category A

Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation

Category B

Original source/host: Animal (historic hybridoma) OR naïve, non-immunised animal B cell-derived in vitro antibody display library
Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
Recombinantly reformatted hybridomas are included as they align with the May 2020 EURL ECVAM recommendation, which permits continued use of existing, sequenced, and well-characterised hybridomas to produce recombinant monoclonal antibodies in vitro, as animals are no longer directly involved
Naïve, non-immunised animal B cell-derived in vitro antibody display libraries align with the May 2020 EURL ECVAM recommendation to no longer authorise the development and production of antibodies through animal immunisation

Category C

Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation

Category D

Original source/host: Animal OR naïve, non-immunised animal B cell-derived in vitro antibody display library
Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation

Category E

Original source/host: Animal
Discovery method: immunisation-based selection post 2020
Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation

Category F

Original source/host: Animal
Discovery method: immunisation-based selection post 2020
Production: Recombinant expression with animal-derived biomaterials used in production or final formulation

Category G

Original source/host: Unknown
Discovery method: Unknown
Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation

Uncategorised Antibodies

Uncategorised Antibodies have Antibody/Binder Origins set in such a way as to prevent them from being assigned to a valid Antibody Category.

Click here to view all Antibody Category descriptions and to search directly by Antibody Category

Category A
- Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
- Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
- Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
Search
Category B
- Original source/host: Animal (historic hybridoma) OR naïve, non-immunised animal B cell-derived in vitro antibody display library
- Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
- Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
- Recombinantly reformatted hybridomas are included as they align with the May 2020 EURL ECVAM recommendation, which permits continued use of existing, sequenced, and well-characterised hybridomas to produce recombinant monoclonal antibodies in vitro, as animals are no longer directly involved
- Naïve, non-immunised animal B cell-derived in vitro antibody display libraries align with the May 2020 EURL ECVAM recommendation to no longer authorise the development and production of antibodies through animal immunisation
Search
Category C
- Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
- Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
- Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation
Search
Category D
- Original source/host: Animal OR naïve, non-immunised animal B cell-derived in vitro antibody display library
- Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
- Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation
Search
Category E
- Original source/host: Animal
- Discovery method: immunisation-based selection post 2020
- Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
Search
Category F
- Original source/host: Animal
- Discovery method: immunisation-based selection post 2020
- Production: Recombinant expression with animal-derived biomaterials used in production or final formulation
Search
Category G
- Original source/host: Unknown
- Discovery method: Unknown
- Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
Search

3951-3960 of 4090 results

Catalogue Number:

PX-TA1609

Category:

Tinurilimab Biosimilar – Anti-CEACAM6 mAb – Research Grade

Target:	CEACAM6
Target Alias Name:	Tinurilimab /BAY-1834942/CEACAM6/anti-CEACAM6
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1-kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1487

Category:

Tiragolumab Biosimilar – Anti-TIGIT/ VSIG9/ VSTM3 mAb – Research Grade

Target:	TIGIT/ VSIG9/ VSTM3
Target Alias Name:	Tiragolumab/MTIG-7192-A/MTIG-7192A/MTIG7192A/RG-6058/RO-7092284/RO7092284/TIGIT/ VSIG9/ VSTM3/anti-TIGIT/ VSIG9/ VSTM3
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1-kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1726

Category:

Tirnovetmab Biosimilar – Anti-IL31 (Canine) mAb – Research Grade

Target:	IL31 (Canine)
Target Alias Name:	Tirnovetmab/IMMUNOGLOBULIN G-B/ ANTI-(CANIS FAMILIARIS INTERLEUKIN 31) (CANIS FAMILIARIS-MUS MUSCULUS MONOCLONAL KIND-016 .GAMMA.B-CHAIN)/ DISULFIDE WITH CANIS FAMILIARIS-MUS MUSCULUS MONOCLONAL KIND-016 .KAPPA.-CHAIN/ DIMER/IL31 (Canine)/anti-IL31 (Canine)
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG2/Kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1479

Category:

Tislelizumab Biosimilar – Anti-PDCD1/ PD1/ CD279 mAb – Research Grade

Target:	PDCD1/ PD1/ CD279
Target Alias Name:	Tislelizumab/BGB-A317/PDCD1/ PD1/ CD279/anti-PDCD1/ PD1/ CD279
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG4-kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1402

Category:

Tisotumab Biosimilar – Anti-F3 / CD142 mAb – Research Grade

Target:	F3 / CD142
Target Alias Name:	Tisotumab/HuMax-TF/F3 / CD142/anti-F3 / CD142
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1-kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1032

Category:

Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade

Target:	Covid Spike RBD
Target Alias Name:	Tixagevimab/Tixagevimab/AZD8895/Covid Spike RBD/anti-Covid Spike RBD
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PTX18819-100

Category:

TNFa / TNF-alpha Monoclonal Antibody CDP571

Target:	TNFa
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG4-kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PTX18689-100

Category:

TNFa / TNF-alpha Monoclonal Monoclonal Antibody 5B11

Target:	TNFa
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1
Host Species:	Mouse
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PTX20632

Category:

TNFSF15/TL1A Monoclonal Antibody

Target:	TNFSF15
Target Alias Name:	Anti-TNFSF15/ Vascular endothelial cell growth inhibitor/ VEGI/ Tumor necrosis factor ligand superfamily member 15/ TL1/ TNF ligand-related molecule 1
Species Reactivity:	Other
Application:	ELISA
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1/ kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA2074

Category:

Tobemstomig Biosimilar – Anti-PD1 and LAG3 mAb – Research Grade

Target:	PD1 and LAG3
Target Alias Name:	anti-PD1/ Programmed cell death protein 1/ Protein PD-1/ hPD-1/ PDCD1/ CD279/ LAG3/ LAG-3/ CD223
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1-kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Viewing 3951-3960 of 4090 results

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.